SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001725160-22-000164
Filing Date
2022-09-12
Accepted
2022-09-12 07:06:17
Documents
4
Period of Report
2022-09-09

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_166298076262776.html 3  
1 FORM 3 wf-form3_166298076262776.xml 3 1733
2 POWER OF ATTORNEY FOR JAN SKVARKA HTM skvarkajan-zntlpowerofat.htm EX-24 5420
3 POWER OF ATTORNEY FOR JAN SKVARKA GRAPHIC 1 skvarkajan-zntlpowerofat001.jpg GRAPHIC 240608
4 POWER OF ATTORNEY FOR JAN SKVARKA GRAPHIC 2 skvarkajan-zntlpowerofat002.jpg GRAPHIC 98530
  Complete submission text file 0001725160-22-000164.txt   476051
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address
Skvarka Jan (Reporting) CIK: 0001838042 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 221237360